January 18, 2022 – iAnthus Capital Holdings, Inc. (“iAnthus” or the “Company”) (CSE: IAN) (OTCPK: ITHUF), which owns, operates and partners with regulated cannabis operations across the United States, announces the resignation of Robert M. Whelan, Jr. from its Board of Directors. Mr. Whelan joined the Company on December 5, 2019 as part of the formation of the Company’s independent Board of Directors.
“Speaking on behalf of the entire iAnthus team, we have been very fortunate to have Bob serve on the Board of Directors for the past two years. We greatly benefited from Bob’s extensive professional background and the strategic insights that he brought to the board as Lead Independent Director,” said Randy Maslow, iAnthus President, Interim Chief Executive Officer and a Director. “We thank Bob for his valuable contributions to the Company and wish him the best in his retirement.”
Mr. Whelan added: “It has been a pleasure working with the entire iAnthus team and I wish the Company and its dedicated employees nothing but the best for the future.”
iAnthus owns and operates licensed cannabis cultivation, processing and dispensary facilities throughout the United States. For more information, visit www.iAnthus.com.
COVID-19 Risk Factor
The Company may be impacted by business interruptions resulting from pandemics and public health emergencies, including those related to COVID-19. An outbreak of infectious disease, a pandemic, or a similar public health threat, such as the recent outbreak of COVID-19, or a fear of any of the foregoing could adversely impact the Company by causing operating, manufacturing, supply chain, and project development delays and disruptions, labor shortages, travel, and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how the Company may be affected if such a pandemic persists for an extended period of time, including as a result of the waiver of regulatory requirements or the implementation of emergency regulations to which the Company is subject. Although the Company has been deemed essential and/or has been permitted to continue operating its facilities in the states in which it cultivates, processes, manufactures, and sells cannabis during the pendency of the COVID-19 pandemic, there is no assurance that the Company’s operations will continue to be deemed essential and/or will continue to be permitted to operate. The Company may incur expenses or delays relating to such events outside of its control, which could have a material adverse impact on its business, operating results, financial condition, and the trading price of the Company’s common shares.